Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 2/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 11/20 | 0.36 |
| ▸ | IDO1 | P14902 | 4/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31663068 | 0.80 | CYP1A2 (0.32) | CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL31663292 | 0.78 | DHODH (0.41) | DHODHHCAR2CYP1A2CYP3A4 | |
| SCHEMBL16478394 | 0.76 | DHODH (0.39) | DHODHHCAR2IDO1CYP2A6 | |
| SCHEMBL15414568 | 0.74 | KDM4E (0.37) | HCAR2AKT1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL709887 | 0.73 | CYP1A2 (0.40) | AKT1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL1228806 | 0.72 | FFAR1 (0.41) | AKT1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL14098208 | 0.70 | ALDH1A1 (0.41) | CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL15414235 | 0.69 | XIAP (0.35) | HCAR2CYP1A2CYP3A4 | |
| SCHEMBL21087260 | 0.68 | NPSR1 (0.43) | CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL16515478 | 0.68 | GABRA1 (0.38) | AKT1CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025149628-A1 | PIPERIDINE DERIVATIVES AS INHIBITORS OF NICOTINAMIDE N-METHYL TRANSFERASE | ASTRAZENECA AB (SE) | 2025-07-17 | — | — | WO | disclosed |